LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023)

LENZ Therapeutics (LENZ) has 4 years of Preferred Stock Liabilities data on file, last reported at $143.4 million in Q4 2023.

• Quarterly Preferred Stock Liabilities rose 1349.41% year-over-year to $143.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $143.4 million (up 1349.41% YoY) and the FY2023 annual result came in at $143.4 million, up 1349.41% from the prior year.
• Preferred Stock Liabilities rose to $143.4 million in Q4 2023 per LENZ's latest filing, from $44.6 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $150.5 million in Q1 2021 and bottomed at $5.9 million in Q2 2023.
• The 4-year median for Preferred Stock Liabilities is $11.5 million (2020), against an average of $49.2 million.
• Peak annual rise in Preferred Stock Liabilities reached 1349.41% in 2023, while the deepest fall reached 1349.41% in 2023.
• Tracing LENZ's Preferred Stock Liabilities over 4 years: stood at $55.6 million in 2020, then soared by 170.69% to $150.5 million in 2021, then plunged by 93.43% to $9.9 million in 2022, then surged by 1349.41% to $143.4 million in 2023.
• Per Business Quant, the three latest LENZ Preferred Stock Liabilities figures stand at $143.4 million (Q4 2023), $44.6 million (Q3 2023), and $5.9 million (Q2 2023).

Peer Comparison